News

Law.com · 3d

Writing Strong Antibody Claims: Avoiding or Addressing USPTO Rejections for Written Description and Enablement

Many patent applicants currently face difficulty in obtaining antibody claims because of written description and enablement rejections under 35 U.S.C. §112(a). The USPTO routinely rejects claims as too broad.
Icon for www.the-scientist.comThe Scientist · Jan 17, 2024

USPTO Issues Biotech Patent Guidelines

In light of several high-profile court cases on patenting of DNA sequences, the U.S. Patent and Trademark Office (USPTO) in June issued interim guidelines for helping patent examiners determine if the so-called "written description" requirement for patent ...
Icon for www.jdsupra.comJD Supra · 27d

End of the Road for Jepson Format Claims in the Life Sciences?

7 The ’690 application was rejected multiple times at the USPTO. After the examiner finally rejected the pending claims for lack of written description, Xencor appealed to the Patent Trial and ...